
"Revolutionary Tumor-Freezing Technology Offers Minimally Invasive Breast Cancer Treatment"
IceCure Medical Ltd. is set to submit results from a cryoablation study to the FDA, potentially offering a minimally invasive alternative to surgery for early-stage breast cancer. The study showed positive topline results, with 96.39% of patients being local recurrence-free after treatment with ProSense®. If approved, this technology could revolutionize the treatment of early-stage breast cancer, providing a safer and more effective option than traditional lumpectomy procedures.


